Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback